Lowenstein Sandler represented issuer Celldex Therapeutics, Inc. (Celldex) (Nasdaq: CLDX) in connection with the company’s $287.5 million public offering of common stock. Jefferies, SVB Leerink, Guggenheim Securities, and Cantor Fitzgerald acted as joint book-running managers for the offering. LifeSci Capital and H.C. Wainwright & Co. acted as co-lead managers for the offering.

Celldex is a clinical-stage biotechnology company dedicated to developing monoclonal and bispecific antibodies that address devastating diseases for which available treatments are inadequate.

The Lowenstein team was led by Anthony O. Pergola and Kate Basmagian and included Michael J. LernerRobert J. Paradiso, and Kaitlyn M. Baietto.

About Lowenstein Sandler LLP
Lowenstein Sandler is a national law firm with over 350 lawyers based in New York, Palo Alto, New Jersey, Utah, and Washington, D.C. The firm represents leaders in virtually every sector of the global economy, with particular emphasis on investment funds, life sciences, and technology. Recognized for its entrepreneurial spirit and high standard of client service, the firm is committed to the interests of its clients, colleagues, and communities.

Kevin Iredell
Chief Marketing Officer
Lowenstein Sandler LLP
T: +1 973.597.6130
E: kiredell@lowenstein.com